Abstract
Objective
Metformin-induced [F-18] fluorodeoxyglucose (FDG) bowel uptake can hinder positron emission tomography/computed tomography (PET/CT) evaluation of the bowel. This study aimed to investigate the segmental bowel uptake of FDG according to metformin discontinuation times up to 72 h.
Methods
We retrospectively divided 240 diabetic patients into four groups: metformin discontinuation <24 h (group A; n = 86), 24–48 h (group B; n = 40), 48–72 h (group C; n = 12), and no metformin (control group; n = 102). Segmental FDG bowel uptakes were measured visually (four-point scale) and semi-quantitatively (maximum standardized uptake value).
Results
Compared with the control group, FDG uptake increased significantly from the ileum to the rectosigmoid colon in group A, from the transverse to the rectosigmoid colon in group B, and from the descending colon to the rectosigmoid colon in group C in both visual and semi-quantitative analyses.
Conclusions
Metformin discontinuation for <72 h is likely suboptimal for PET/CT image interpretation, especially with respect to the distal segments of the colon.
Similar content being viewed by others
References
Bybel B, Greenberg ID, Paterson J, Ducharme J, Leslie WD. Increased F-18 FDG intestinal uptake in diabetic patients on metformin: a matched case–control analysis. Clin Nucl Med. 2011;36:452–6.
Gontier E, Fourme E, Wartski M, Blondet C, Bonardel G, Le Stanc E, et al. High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging. 2008;35:95–9.
Ozulker T, Ozulker F, Mert M, Ozpacaci T. Clearance of the high intestinal 18F-FDG uptake associated with metformin after stopping the drug. Eur J Nucl Med Mol Imaging. 2010;37:1011–7.
Surasi DS, Bhambhvani P, Baldwin JA, Almodovar SE, O’Malley JP. 18F-FDG PET and PET/CT patient preparation: a review of the literature. J Nucl Med Technol. 2014;42:5–13.
Oh JR, Song HC, Chong A, Ha JM, Jeong SY, Min JJ, et al. Impact of medication discontinuation on increased intestinal FDG accumulation in diabetic patients treated with metformin. AJR Am J Roentgenol. 2010;195:1404–10.
Abele JT, Fung CI. Effect of hepatic steatosis on liver FDG uptake measured in mean standard uptake values. Radiology. 2010;254:917–24.
Abikhzer G, Alabed YZ, Azoulay L, Assayag J, Rush C. Altered hepatic metabolic activity in patients with hepatic steatosis on FDG PET/CT. AJR Am J Roentgenol. 2011;196:176–80.
Dostbil Z, Varoglu E, Serdengecti M, Kaya B, Onder H, Sari O. Evaluation of hepatic metabolic activity in non-alcoholic fatty livers on 18FDG PET/CT. Rev Esp Med Nucl Imagen Mol. 2013;32:156–61.
Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J. SEER survival monograph: cancer survival among adults: US SEER Program, 1988–2001, patient and tumor characteristics. In: National Cancer Institute, SEER Program, NIH Pub. No. 07-6215 2007. http://seer.cancer.gov/archive/publications/survival/seer_survival_mono_lowres.pdf. Accessed 2 June 2016.
Treglia G, Taralli S, Salsano M, Muoio B, Sadeghi R, Giovanella L. Prevalence and malignancy risk of focal colorectal incidental uptake detected by 18F-FDG-PET or PET/CT: a meta-analysis. Radiol Oncol. 2014;48:99–104.
Ikeda T, Iwata K, Murakami H. Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine. Biochem Pharmacol. 2000;59:887–90.
Lorch E. Inhibition of intestinal absorption and improvement of oral glucose tolerance by biguanides in the normal and in the streptozotocin-diabetic rat. Diabetologia. 1971;7:195–203.
Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica. 1994;24:49–57.
Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574–9.
Bailey CJ, Mynett KJ, Page T. Importance of the intestine as a site of metformin-stimulated glucose utilization. Br J Pharmacol. 1994;112:671–5.
Penicaud L, Hitier Y, Ferre P, Girard J. Hypoglycaemic effect of metformin in genetically obese (fa/fa) rats results from an increased utilization of blood glucose by intestine. Biochem J. 1989;262:881–5.
Drozdowski LA, Thomson AB. Intestinal sugar transport. World J Gastroenterol. 2006;12:1657–70.
Wright EM, Martin MG, Turk E. Intestinal absorption in health and disease—sugars. Best Pract Res Clin Gastroenterol. 2003;17:943–56.
Massollo M, Marini C, Brignone M, Emionite L, Salani B, Riondato M, et al. Metformin temporal and localized effects on gut glucose metabolism assessed using 18F-FDG PET in mice. J Nucl Med. 2013;54:259–66.
Wilcock C, Bailey CJ. Sites of metformin-stimulated glucose metabolism. Biochem Pharmacol. 1990;39:1831–4.
Chai TF, Hong SY, He H, Zheng L, Hagen T, Luo Y, et al. A potential mechanism of metformin-mediated regulation of glucose homeostasis: inhibition of Thioredoxin-interacting protein (Txnip) gene expression. Cell Signal. 2012;24:1700–5.
Oka S, Liu W, Masutani H, Hirata H, Shinkai Y, Yamada S, et al. Impaired fatty acid utilization in thioredoxin binding protein-2 (TBP-2)-deficient mice: a unique animal model of Reye syndrome. Faseb J. 2006;20:121–3.
Shaked M, Ketzinel-Gilad M, Cerasi E, Kaiser N, Leibowitz G. AMP-activated protein kinase (AMPK) mediates nutrient regulation of thioredoxin-interacting protein (TXNIP) in pancreatic beta-cells. PLoS One. 2011;6:e28804.
Roy FN, Beaulieu S, Boucher L, Bourdeau I, Cohade C. Impact of intravenous insulin on 18F-FDG PET in diabetic cancer patients. J Nucl Med. 2009;50:178–83.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Suk Hyun Lee, Soyoung Jin, Hyo Sang Lee, Jin-Sook Ryu, and Jong Jin Lee declare that they have no conflict of interest.
Funding
None to declare.
Rights and permissions
About this article
Cite this article
Lee, S.H., Jin, S., Lee, H.S. et al. Metformin discontinuation less than 72 h is suboptimal for F-18 FDG PET/CT interpretation of the bowel. Ann Nucl Med 30, 629–636 (2016). https://doi.org/10.1007/s12149-016-1106-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-016-1106-7